Fate Therapeutics, Inc.
(NASDAQ : FATE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.99%194.781.3%$536.34m
GILDGilead Sciences, Inc.
-0.24%66.010.9%$359.16m
ALXNAlexion Pharmaceuticals, Inc.
-4.85%102.602.0%$309.75m
ILMNIllumina, Inc.
1.31%302.183.5%$307.20m
BIIBBiogen Inc.
-1.25%235.721.3%$295.96m
CELGCelgene Corporation
0.14%98.741.3%$288.77m
SRPTSarepta Therapeutics, Inc.
-2.29%82.9414.6%$174.77m
AAgilent Technologies, Inc.
0.52%76.801.6%$174.25m
VRTXVertex Pharmaceuticals Incorporated
-0.76%174.661.9%$173.21m
REGNRegeneron Pharmaceuticals, Inc.
-2.00%282.372.6%$169.16m
EXASExact Sciences Corporation
-1.74%105.0124.1%$132.84m
ACADACADIA Pharmaceuticals Inc.
-3.76%41.0013.9%$110.65m
INCYIncyte Corporation
-1.33%78.052.5%$84.58m
BMRNBioMarin Pharmaceutical Inc.
0.67%75.504.3%$71.70m
ALDRAlder Biopharmaceuticals, Inc.
0.54%18.8010.2%$64.28m

Company Profile

Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.